Quoin Pharmaceuticals, Ltd.
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Quoin Pharmaceuticals, Ltd. generated cash of -$7,864,429, which is more than the previous year. Cash used in financing activities reached the amount of $5,216,683 last year. Net change in cash is therefore -$459,430.
Cash Flow
| 2015 | -1.98M | 817.08K | 1.64M |
|---|---|---|---|
| 2017 | -4.97M | 2.82M | 4.43M |
| 2018 | -6.30M | 3.65M | 0 |
| 2019 | -1.29M | -108K | 1.29M |
| 2020 | -1.33M | -125K | 1.78M |
| 2021 | -5.72M | -625K | 13.50M |
| 2022 | -8.48M | -10.14M | 14.00M |
| 2023 | -7.86M | 2.18M | 5.21M |
QNRX Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2015 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 2.86M | 7.48M | 323.83K | 5.24M | 40 | 0 | 1.63M | 526.71K |
Operating activities | ||||||||
Net income | -8.68M | -9.38M | -21.46M | -2.09M | -1.56M | 3.73M | -7.90M | -2.61M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 103.70K | 104.04K | 104.04K | 104.04K | 20.71K | 122K | 104.22K | 18.27K |
Stock-based compensation expense | 1.09M | 764.00K | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 1.09M | 764.00K | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 0 | 0 | 0 | 60.19K | 108.05K | 0 | 131.67K | -84.41K |
Inventories | 0 | 0 | 0 | -60.19K | 358.68K | 0 | 0 | 0 |
Accounts payable | 53.78K | -217.80K | 1.34M | 227.31K | 240.83K | 0 | 114.02K | 343.04K |
Cash generated by operating activities | -7.86M | -8.48M | -5.72M | -1.33M | -1.29M | -6.30M | -4.97M | -1.98M |
Investing activities | ||||||||
Purchases Of Investments | -18.09M | -9.89M | 0 | 0 | -4.20K | 0 | -2.56M | 0 |
Investments In Property Plant And Equipment | 0 | -250K | -625K | -125K | -123K | -175K | -74.52K | -85.44K |
Acquisitions Net | 0 | 0 | 0 | 0 | 1.68K | 0 | 0 | 19.81K |
Cash generated by investing activities | 2.18M | -10.14M | -625K | -125K | -108K | 3.65M | 2.82M | 817.08K |
Financing activities | ||||||||
Common Stock Issued | 5.83M | 14.81M | 10.10M | -142.32K | 6.28M | 0 | 4.43M | 1.64M |
Payments for dividends | 0 | -65.26M | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -14.81M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -311.67K | -3.47M | -916.36K | 0 | 0 | 0 | 0 |
Cash used in financing activities | 5.21M | 14.00M | 13.50M | 1.78M | 1.29M | 0 | 4.43M | 1.64M |
Net Change In Cash | -459.43K | -4.62M | 7.15M | -4.91M | 5.24M | -2.64M | 2.32M | 478.92K |
Cash at end of period | 2.40M | 2.86M | 7.48M | 323.83K | 5.24M | -2.64M | 3.95M | 1.00M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |